Parand Darou Pharma  Parand Darou Pharma

X
[{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit's AQV-1122 COVID-19 Vaccine Patent Approval Fast Tracked by USPTO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files IND with FDA for DTX-021, a New Botulinum Toxin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files Two IND's For Its Botulinum Toxin With FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files Investigational New Drug Application for its Flagship Intradermal Injection of Botulinum Toxin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by Aquavit Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Dermatox (botulinum Toxin Type A-aqu) is a neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. It is being investigated for the improvement of skin quality and reduction of fine lines for face and neck.

            Lead Product(s): AqubotulinumtoxinA

            Therapeutic Area: Dermatology Product Name: Dermatox

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            DTX-023 (botulinum toxin type A) is a neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. It is being investigated for primary axillary hyperhidrosis and palmar hyperhidrosis.

            Lead Product(s): Botulinum toxin type A

            Therapeutic Area: Dermatology Product Name: DTX-023

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Dermatox (DTX-021) is a botulinum toxin type A drug, highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum.

            Lead Product(s): Botulinum toxin type A

            Therapeutic Area: Dermatology Product Name: Dermatox

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Aquavit received a notice of allowance through the USPTO's Fast-Track Prioritized Examination Pilot Program (PEPP) for the application of the company's proprietary technology for self-injectable Covid 19 vaccination (AQV-1122).

            Lead Product(s): AQV-1122

            Therapeutic Area: Infections and Infectious Diseases Product Name: AQV-1122

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY